Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Feb 20 (Reuters) - Eli Lilly (LLY.N), opens new tab is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the pharmaceutical company from preparing for its launch.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Danish drugmaker Novo Nordisk and Eli Lilly currently dominate the market for weight-loss treatments with their injectable drugs. Novo is studying the pill version of its experimental drug ...